Abstract

The SPORE's Developmental Research Program consists of two components: A) the continued funding and tracking of 1-year pilot projects, and B) the funding of two new longer-term developmental projects. To date, this SPORE program has funded 15 pilot projects (with 3 renewals for an additional year) from a pool of 25 applicants; the pilot project program and these 15 projects are reviewed in the following section. In years 04-08 we intend to support an additional 5 -10 pilot projects per year. In addition, as proposed in the PI's Introduction to this SPORE renewal application, the SPORE's Developmental Research Program will also support two new developmental projects: i) DP#1, """"""""Ligand mediated targeting of retrovirus to breast cancer,"""""""" Y.W. Kan, PI; and ii) DP#2, """"""""Genomic instability in carcinogenesis of the breast,"""""""" T.D. Tisty, PI. These unique and highly promising developmental projects are being given special emphasis since they will bring important new dimensions to our overall SPORE. Each of these two developmental project proposals included in the following section is presented independently and in standard NIH project application format.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058207-08S3
Application #
6502908
Study Section
Project Start
1999-08-01
Project End
2002-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
2001
Total Cost
$206,819
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications